Suggested remit: To appraise the clinical and cost effectiveness of eflornithine within its marketing authorisation for treating high-risk neuroblastoma with complete or partial response after immunotherapy.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 4060

Provisional Schedule

Committee meeting 10 April 2025
Expected publication 25 June 2025

Project Team

Project lead Celia Mayers

Email enquiries

Stakeholders

Companies sponsors Norgine (eflornithine)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Cancer52
  Childhood Cancer Parents Alliance
  Children with Cancer UK
  Children’s Cancer and Leukaemia Group
  Contact
  Gene People
  Genetic Alliance UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Mitchell’s Miracles
  Neuroblastoma UK
  Solving Kids’ Cancer UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Teenage Cancer Trust
  Tenovus Cancer Care
  Together for Shorter Lives
  Young Lives vs Cancer
Professional groups Association of Cancer Physicians
  British Institute of Radiology
  British Paediatric Neurology Association
  British Psychosocial Oncology Society
  Cancer Research UK
  Children’s Cancer and Leukaemia Group
  Neonatal & Paediatric Pharmacists Group
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics and Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association for Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Childhood Cancer Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
06 September 2024 Invitation to participate
19 July 2024 Please note that following conversations between NICE and the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early September 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-November 2024. Draft scope consultation will be issued in late July 2024.
09 November 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy. Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any developments and will update interested parties as and when the situation changes.
17 March 2022 - 14 April 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 March 2022 In progress. Scoping commenced
28 January 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual